COMPANY

Rani Therapeutics

HQ: San Jose, CA source · ranitherapeutics.com ↗ · West Coast

Keywords: antibody monoclonal antibody Obesity Not Determined PG-102 RT-111 RT-102

Location: San Jose, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $60.26M (Form D filed Nov 10, 2025). SEC Form D 0001231919-25-000450 (Nov 10, 2025)
Evidence (1 event)
- Nov 10, 2025 · SEC Form D 0001231919-25-000450
  Name of Issuer: Rani Therapeutics Holdings, Inc.; CIK: 1856725; Address: San Jose, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-23; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 60255052; Total Amount Sold: 60255052; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Dec 30, 2025 Trial start S: An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. source ↗
Jul 15, 2025 Raise Follow-on offering — Registered direct: $3M (total, as published), announced Jul 15, 2025. Source: company release on GlobeNewswire. source ↗
Oct 15, 2024 Raise Follow-on offering — Registered direct: $10M (total, as published), announced Oct 15, 2024. Source: company release on GlobeNewswire. source ↗
Aug 30, 2023 Trial start Phase 1: Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule source ↗
Feb 21, 2022 Trial start Phase 1: Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule source ↗
Jun 1, 2021 Trial start Not phased (device or behavioral study): Pill Swallow Study source ↗
Jul 9, 2019 Trial start Phase 1: A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform source ↗

Dec 1, 2026 (ESTIMATED) · S · An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. · NCT06891287

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $13.0M. Last 2 years.

Jul 15, 2025 Follow-on offering — Registered direct: $3M (total, as published), announced Jul 15, 2025. Source: company release on GlobeNewswire. source ↗
Oct 15, 2024 Follow-on offering — Registered direct: $10M (total, as published), announced Oct 15, 2024. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06891287	An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.	S	Recruiting	Dec 30, 2025	Dec 1, 2026 (estimated)
NCT04911296	Pill Swallow Study	Not phased (device or behavioral study)	Completed	Jun 1, 2021	Aug 27, 2021 (actual)
NCT05890118	Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule	Phase 1	Completed	Aug 30, 2023	Nov 28, 2023 (actual)
NCT05164614	Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule	Phase 1	Completed	Feb 21, 2022	Oct 10, 2022 (actual)
NCT03798912	A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform	Phase 1	Completed	Jul 9, 2019	Feb 17, 2020 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2025-11-10 Raise Private raise (SEC Form D): $60.3M sold; issuer “Rani Therapeutics Holdings, Inc.”. Verified from the SEC filing. SEC filing ↗